The North America wound care biomaterials market was valued at USD 3.2 billion in 2025. This market is expected to reach USD 6.9 billion by 2036, growing from USD 3.4 billion in 2026, at a CAGR of 7.3% from 2026 to 2036.

The market covers the biomaterials used in advanced and bioactive wound care, including natural polymers such as collagen, alginate, chitosan, and hyaluronic acid, and bioengineered extracellular matrices and skin substitutes derived from human, animal, or plant sources. Demand is driven by the high and rising burden of chronic wounds, particularly diabetic foot ulcers, venous leg ulcers, and pressure ulcers, by an aging population, and by the shift from traditional dressings toward biomaterials that actively support tissue regeneration. The United States accounts for the large majority of regional demand, supported by a deep base of manufacturers and a specialised wound care infrastructure, and the market is shaped by reimbursement policy, most immediately the changes to Medicare payment for skin substitutes that took effect in 2026.

Key Highlights – North America Wound Care Biomaterials Market

• The North America wound care biomaterials market is expected to reach USD 6.9 billion by 2036, at a CAGR of 7.3% from 2026 to 2036, driven by the chronic-wound burden and the shift toward regenerative biomaterials.
• Diabetes underpins chronic-wound demand. The U.S. Centers for Disease Control and Prevention reports that about 38.4 million Americans, roughly 11.6% of the population, have diabetes, and about 12% of people with diabetes develop a foot ulcer in their lifetime.
• Chronic wounds are a large clinical burden. Over 6.5 million people in the United States have chronic, non-healing wounds, and up to 3 million leg ulcers occur each year, sustaining demand for advanced biomaterials.
• Collagen and skin substitutes lead product development. Natural biomaterials such as collagen, chitosan, alginate, and hyaluronic acid, and bioengineered skin substitutes and extracellular matrices, are central to bioactive wound care because they mimic the healing environment of the body.
• Reimbursement reset the skin-substitute segment in 2026. From 1 January 2026, the Centers for Medicare & Medicaid Services reclassified skin substitutes as incident-to supplies and moved to a flat payment of about USD 127.14 per square centimetre, materially changing the economics of the segment.
• Consolidation continued. Solventum agreed to acquire Acera Surgical for about USD 725 million, announced in December 2025, adding proprietary scaffold technology, as diversified device majors continue to absorb niche biomaterials innovators.
• Key companies include Smith & Nephew plc, Solventum Corporation, Convatec Group PLC, Coloplast A/S, and Integra LifeSciences Holdings Corporation.

Report Overview

The North America wound care biomaterials market covers the biomaterials used in advanced and bioactive wound care products, including natural polymers such as collagen, alginate, chitosan, hyaluronic acid, and cellulose, and bioengineered extracellular matrices and skin substitutes derived from human, animal, or plant sources. It spans wound dressings, skin substitutes and grafts, matrices and scaffolds, and topical biomaterials used to treat chronic and acute wounds. Traditional gauze and inert dressings without a biomaterial function are outside the scope except where they carry a bioactive biomaterial. Demand is concentrated in the United States, supported by a deep base of manufacturers and a specialised wound care infrastructure, and is shaped by reimbursement policy, most immediately the 2026 changes to Medicare payment for skin substitutes. This report examines the size, drivers, segmentation, countries, pricing, competition, recent developments, and outlook of the market, and provides recommendations for participants. Sizing is built bottom-up from wound prevalence, procedure volumes, and product-level demand across biomaterials and channels.

Key Market Dynamics

Market Drivers

The main drivers of the North America wound care biomaterials market are the burden of chronic wounds, the aging population, and the shift toward regenerative biomaterials. The chronic-wound burden is large and rising: the CDC reports about 38.4 million Americans, roughly 11.6% of the population, have diabetes, and about 12% of people with diabetes develop a foot ulcer over their lifetime, while more than 6.5 million people in the United States have chronic, non-healing wounds and up to 3 million leg ulcers occur each year. These wounds are costly and slow to heal, and the total cost of managing diabetes in the United States was estimated at about USD 413 billion in 2022, which supports investment in biomaterials that improve healing. The aging population increases the incidence of pressure ulcers, venous leg ulcers, and comorbidities that impair healing, enlarging the treated population. The shift from traditional dressings toward biomaterials that actively support tissue regeneration, such as collagen, extracellular matrices, and bioengineered skin substitutes, raises the value per treatment. These factors, chronic-wound burden, aging, and the shift to regenerative biomaterials, are the main drivers.

Key Opportunities

The market offers opportunities in diabetic foot ulcer care, in bioengineered skin substitutes, and in home and outpatient care. Diabetic foot ulcers are the largest opportunity, because they affect about 12% of the roughly 38 million Americans with diabetes over their lifetime, are prone to non-healing and amputation, and are a priority indication for advanced biomaterials; several manufacturers, including Aroa Biosurgery, have targeted non-healing diabetic foot ulcers as a core indication in 2026 programs. Bioengineered skin substitutes and extracellular matrices, derived from amniotic and placental tissue, ovine or porcine matrices, and fish skin, offer a high-value opportunity for hard-to-heal wounds, though the 2026 Medicare payment changes will reshape the economics and reward products with strong clinical evidence. Home and outpatient wound care, growing as care shifts out of the hospital, creates demand for biomaterials suited to less intensive settings. These areas, diabetic foot ulcers, skin substitutes, and home and outpatient care, are the main opportunities, alongside antimicrobial and antibiofilm biomaterials that address wound infection.

Market Trends

Current trends include the move to regenerative and bioactive biomaterials, product innovation in matrices and antimicrobials, consolidation, and reimbursement-driven change. Bioactive dressings, including collagen-based products, growth factors, and bioengineered skin substitutes, are taking share from inert dressings; the advanced wound dressing segment held about 31.8% of the wider wound care market in 2025, reflecting this shift. Product innovation continues, illustrated by collagen-alginate hybrid dressings such as Fibracol Plus, a 90% collagen and 10% alginate product, and by newer nitric-oxide antimicrobial dressings such as Convatec ConvaNiox launching in 2026. Consolidation is concentrating the field, with Solventum, Smith & Nephew, and Mölnlycke Health Care absorbing niche biomaterials innovators while Organogenesis and MiMedx specialise in amniotic and placental matrices. Reimbursement is a defining force, as the 2026 Medicare reclassification of skin substitutes and the move to a flat per-square-centimetre payment change how products are priced and selected. These trends indicate a market shifting toward higher-value, evidence-backed biomaterials under tighter reimbursement.

Report Summary

Segmental Analysis

Market by Material Type

By material type, the market comprises collagen, alginate, chitosan, hyaluronic acid, cellulose and other polysaccharides, extracellular matrix and skin substitutes, and other biomaterials. Collagen holds the largest share, at about 35% of the market in 2026, with the remaining share divided across the other materials. Collagen is the most widely used wound care biomaterial because it provides a scaffold for cell migration and supports granulation and epithelialisation, and it is used in dressings, gels, powders, and matrices, including collagen-alginate hybrids. Alginate, derived from seaweed, is valued for high exudate absorption and is common in moderate-to-heavy exudate wounds. Chitosan, from crustacean shells, offers haemostatic and antimicrobial properties. Hyaluronic acid supports moisture retention and tissue repair. Cellulose and other polysaccharides serve a range of dressing functions. Extracellular matrix and skin substitutes, derived from amniotic and placental tissue, ovine and porcine matrices, and fish skin, are the high-value biologic segment used for hard-to-heal wounds.

Market by Product Form

By product form, the market comprises dressings, skin substitutes and grafts, matrices and scaffolds, and topical biomaterials. Dressings, including collagen sheets, alginate and hydrocolloid dressings carrying bioactive biomaterials, gels, and powders, are the largest form and the most widely used across wound types. Skin substitutes and grafts, applied to chronic and complex wounds, are a high-value form central to the reimbursement changes of 2026. Matrices and scaffolds, including extracellular matrix products that support tissue rebuilding, are used in deeper and harder-to-heal wounds. Topical biomaterials, including gels and fillers, complete the category. Product form is closely tied to wound severity and care setting, and to the reimbursement pathway that applies to each.

Market by Source

By source, the market comprises natural and biologic biomaterials and synthetic and semi-synthetic biomaterials. Natural and biologic biomaterials lead the market, because materials such as collagen, chitosan, alginate, and hyaluronic acid, and tissue-derived skin substitutes, offer strong biocompatibility and mimic the natural healing environment. Within this group, animal-derived, human tissue-derived, and plant-derived materials serve different applications and carry different regulatory and sourcing considerations. Synthetic and semi-synthetic biomaterials, including engineered polymers and composites, offer consistency, scalability, and design control, and are often combined with natural materials in hybrid products. The balance reflects a clinical preference for biocompatible natural materials alongside the manufacturing advantages of synthetic components.

Market by Wound Type

By wound type, the market comprises chronic wounds and acute wounds. Chronic wounds hold the largest share, at about 65% of the market in 2026, with acute wounds accounting for the remaining share. Chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers, are the primary application for advanced biomaterials because they are slow to heal and benefit most from regenerative products; the more than 6.5 million people in the United States with chronic non-healing wounds anchor this demand. Acute wounds, including surgical wounds, trauma, and burns, use biomaterials to support healing and reduce complications, and are driven by procedure volumes and injury incidence. The weighting toward chronic wounds reflects both their prevalence and the higher use of advanced biomaterials in their care.

Market by End User

By end user, the market comprises hospitals, wound care and specialty clinics, home care, and long-term care and ambulatory surgical centres. Hospitals hold the largest share, at about 40% of the market in 2026, with the remaining share divided across wound care clinics, home care, and long-term and ambulatory settings. Hospitals treat the most complex and acute wounds and use the widest range of biomaterials, including high-value skin substitutes. Wound care and specialty clinics provide focused outpatient management of chronic wounds and are significant users of advanced biomaterials. Home care is a growing setting as management shifts out of the hospital, creating demand for biomaterials suited to less intensive use. Long-term care and ambulatory surgical centres treat older patients and post-surgical wounds. The mix reflects the movement of chronic wound care toward outpatient and home settings.

Geographic Analysis

United States Wound Care Biomaterials Market

The United States is by far the largest market in the region, accounting for the large majority of demand. The scale reflects the size of the population affected: about 38.4 million Americans have diabetes, more than 6.5 million have chronic non-healing wounds, and the aging population increases the incidence of pressure and venous ulcers. Supply is led by a deep base of manufacturers, including Smith & Nephew plc, Solventum Corporation, Integra LifeSciences Holdings Corporation, Organogenesis Holdings Inc., and MiMedx Group, Inc., and a specialised network of wound care centres. Reimbursement is a central factor, and the 2026 Medicare reclassification of skin substitutes and the move to a flat payment of about USD 127.14 per square centimetre are reshaping the economics of the highest-value segment, favouring products with strong clinical evidence. The United States sets the pace for product innovation, clinical evidence, and reimbursement policy across the region.

Canada Wound Care Biomaterials Market

Canada is a significant secondary market with an aging population, a high diabetes burden, and a publicly funded health system that shapes access to advanced biomaterials. Demand is driven by chronic wounds, particularly diabetic foot and pressure ulcers, and provincial funding and wound care programs influence adoption. Supply is drawn from the same multinational manufacturers active in the United States, and Canadian wound care associations and home care programs support the use of advanced dressings and biomaterials. Adoption of higher-value skin substitutes is more measured than in the United States, reflecting funding structures, but the underlying clinical need is comparable.

Pricing Analysis

Pricing in wound care biomaterials spans a wide range, from modestly priced collagen and alginate dressings to high-value bioengineered skin substitutes, and it is closely tied to reimbursement. Advanced dressings carrying biomaterials are priced above traditional dressings to reflect their bioactive function, while skin substitutes and extracellular matrices command far higher prices per application because of their tissue-derived content, processing, and clinical role in hard-to-heal wounds. Reimbursement is the dominant influence on realised prices in the United States, and the 2026 Medicare change, reclassifying skin substitutes as incident-to supplies and moving to a flat payment of about USD 127.14 per square centimetre, directly compresses the pricing of a segment that previously carried wide price variation.

Several factors set price. Material and processing are central, with tissue-derived skin substitutes and extracellular matrices costing far more than polysaccharide dressings because of sourcing, processing, and regulatory requirements. Clinical evidence increasingly determines both price and access, since payers and providers favour products with demonstrated healing outcomes, a factor reinforced by the 2026 reimbursement changes. Regulatory pathway matters, as products cleared as devices, regulated as human tissue, or approved as biologics face different cost and evidence requirements. Care setting and channel affect price, with hospital and specialty-clinic use supporting higher-value products and home care favouring simpler biomaterials. Scale and consolidation influence pricing, as large manufacturers apply manufacturing and distribution efficiency, while the reimbursement reset is expected to pressure margins in the skin-substitute segment and reward cost-effective, evidence-backed products.

Competitive Landscape

The competitive field combines diversified medical-device majors with specialist biomaterials and regenerative-tissue companies. Among the majors, Smith & Nephew plc, Solventum Corporation, Convatec Group PLC, Coloplast A/S, and Mölnlycke Health Care AB offer broad advanced wound care portfolios spanning collagen, alginate, and other biomaterial dressings, and are extending into skin substitutes and matrices; Solventum, formed from the health care business of 3M, agreed to acquire Acera Surgical for about USD 725 million, announced in December 2025, to add scaffold technology. Integra LifeSciences Holdings Corporation is a leader in regenerative matrices, and Baxter International Inc. and Essity AB contribute advanced dressing lines.

Among specialists, Organogenesis Holdings Inc. and MiMedx Group, Inc. focus on amniotic and placental tissue matrices and skin substitutes; Coloplast A/S, through its Kerecis fish-skin graft business, and Aroa Biosurgery Limited, with its ovine extracellular matrix platform, compete in the biologic skin-substitute segment; and MTF Biologics and Celularity Inc. provide tissue-based products. Convatec is launching new biomaterials including the ConvaMatrix porcine collagen matrix and the ConvaNiox nitric-oxide antimicrobial dressing. Competition turns on clinical evidence, breadth of portfolio, regulatory and reimbursement positioning, and manufacturing scale, and the 2026 reimbursement changes are expected to favour companies with strong outcomes data and cost-effective products, while consolidation continues to concentrate the field.

Key Players

The active manufacturers in the market as of September 2026 include:

• Smith & Nephew plc
• Solventum Corporation
• Convatec Group PLC
• Coloplast A/S
• Molnlycke Health Care AB
• Integra LifeSciences Holdings Corporation
• Organogenesis Holdings Inc.
• MiMedx Group, Inc.
• Baxter International Inc.
• Essity AB
• Aroa Biosurgery Limited
• Medline Industries, LP

Voice of Customer

Wound care physician, hospital outpatient centre (United States): "For a non-healing diabetic foot ulcer, an advanced biomaterial can be the difference between healing and amputation, so the clinical value is real. What has changed is the pressure to justify the choice with evidence and cost, especially for skin substitutes under the new payment rules, so I reach first for products with strong outcomes data."

Procurement lead, integrated health system (United States): "The reimbursement reset in 2026 forced us to rationalise a long list of skin-substitute products. We are consolidating around biomaterials with demonstrated healing and a defensible cost per healed wound, rather than paying a wide range of prices for similar products. Evidence and total cost of care now drive the formulary."

Wound care nurse, home health (Canada): "More chronic wound care is happening at home, and we need biomaterials that are simple to apply, manage exudate, and last between visits. Collagen and alginate dressings do a lot of the everyday work, and the priority is reliable healing with fewer dressing changes rather than the most advanced product for every wound."

Analyst Perspective

North American wound care biomaterials is a durable market grounded in a large and rising clinical burden. Diabetes affects about 38 million Americans, more than 6.5 million people have chronic non-healing wounds, and the aging population increases the incidence of pressure and venous ulcers, so the treated population is large and growing independently of economic cycles. The shift from inert dressings toward regenerative biomaterials, including collagen, extracellular matrices, and bioengineered skin substitutes, raises the value per treatment and is the main engine of growth above the general medical-supply rate.

The defining question for the market is reimbursement. The 2026 Medicare changes, reclassifying skin substitutes as incident-to supplies and moving to a flat per-square-centimetre payment, will compress pricing in the highest-value segment and reward products with strong clinical evidence and defensible cost per healed wound; the withdrawal and revision of coverage determinations through late 2025 and into 2026 have added uncertainty that manufacturers and providers are still absorbing. This is a genuine headwind for parts of the skin-substitute segment, and it should temper expectations for the highest-priced products even as overall demand for biomaterials grows. Consolidation is concentrating the field, favouring companies that combine broad portfolios, manufacturing scale, and clinical evidence, while specialists in amniotic, ovine, porcine, and fish-skin matrices retain a role where their outcomes justify it. Companies that pair biocompatible, evidence-backed biomaterials with cost-effectiveness are best positioned as the market shifts toward value.

Key Strategic Developments

• January 2026: The Centers for Medicare & Medicaid Services implemented major payment changes for skin substitutes, reclassifying them as incident-to supplies in the non-facility setting and moving to a flat payment of about USD 127.14 per square centimetre, materially changing the economics of the skin-substitute biomaterials segment and favouring evidence-backed, cost-effective products.
• 2026: Convatec Group PLC advanced the launch of new wound care biomaterials, including the ConvaNiox nitric-oxide-generating antimicrobial and antibiofilm dressing and the ConvaMatrix collagen matrix, extending its bioactive portfolio, and confirmed continued Medicare coverage for its InnovaMatrix product for 2026.
• 2026: Aroa Biosurgery Limited advanced its ovine extracellular matrix programs targeting non-healing diabetic foot ulcers as a core indication, with studies meeting primary endpoints, reinforcing the evidence base for biologic biomaterials.
• December 2025: Solventum Corporation agreed to acquire Acera Surgical for about USD 725 million, adding proprietary regenerative scaffold technology and illustrating the continued absorption of niche biomaterials innovators by device majors as the field consolidates into 2026.
• Through the first three quarters of 2026: Providers and health systems rationalised skin-substitute formularies in response to the reimbursement changes, consolidating around biomaterials with demonstrated healing outcomes and defensible cost per healed wound.

Strategic Recommendations

For manufacturers, the priority is to build and defend clinical evidence and cost-effectiveness, because the 2026 reimbursement changes have made demonstrated healing outcomes and a defensible cost per healed wound the basis for access, particularly in the skin-substitute segment. Companies should align product development and pricing with the new Medicare framework, invest in outcomes studies for priority indications such as diabetic foot ulcers, and combine biocompatible natural biomaterials with manufacturing scale to reach hospitals, clinics, and the growing home care setting. Broadening portfolios across dressings, matrices, and skin substitutes, and pairing them with antimicrobial and antibiofilm capability, strengthens the position against a consolidating field.

For providers and health systems, the recommendation is to rationalise biomaterials selection around evidence and total cost of care, using the reimbursement reset as an opportunity to consolidate around products with demonstrated healing rather than a wide range of similar-priced options, and to match biomaterials to wound severity and care setting. For payers, the evidence supports continuing to tie coverage to clinical outcomes while preserving access to the advanced biomaterials that prevent costly complications such as amputation and hospitalisation. For investors, this is a market to evaluate on clinical evidence, reimbursement positioning, and cost-effectiveness rather than on headline pricing, recognising that the chronic-wound burden provides durable demand while reimbursement change reshapes value within the skin-substitute segment.